Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

被引：26

作者：

Takimoto, CH

Remick, SC

Sharma, S

Mani, S

Ramanathan, RK

Doroshow, JH

Hamilton, A

Mulkerin, D

Graham, M

Lockwood, GF

Ivy, P

Egorin, M

Greenslade, D

Goetz, A

Grem, JL

机构：

[1] Univ Texas, Hlth Sci Ctr, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA

[2] NCI, Med Branch Navy, Natl Naval Med Ctr, Bethesda, MD USA

[3] Univ Hosp Cleveland, Ctr Comprehens Canc, Cleveland, OH 44106 USA

[4] Case Western Reserve Univ, Cleveland, OH 44106 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Albert Einstein Coll Med, Montefiore Hosp, Bronx, NY 10467 USA

[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[8] City Hosp, Duarte, CA USA

[9] NYU, New York, NY USA

[10] Univ Wisconsin, Madison, WI USA

[11] Sanofi Synthelabo Inc, Dept Clin Met & Pharmacokinet, Malvern, PA USA

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 04期

关键词：

D O I：

10.1016/S0093-7754(03)00401-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：20 / 25

页数：6

共 22 条

[1]

Allain P, 2000, DRUG METAB DISPOS, V28, P1379

[2] Inductively coupled plasma mass spectrometry [J].

Beauchemin, D .

ANALYTICAL CHEMISTRY, 2002, 74 (12) :2873-2893

[3] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[4] An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma [J].

Chau, I ;

Webb, A ;

Cunningham, D ;

Hill, M ;

Rao, S ;

Ageli, S ;

Norman, A ;

Gill, K ;

Howard, A ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :786-792

[5]

Chollet P, 1996, ANN ONCOL, V7, P1065

[6] Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients [J].

Dieras, V ;

Bougnoux, P ;

Petit, T ;

Chollet, P ;

Beuzeboc, P ;

Borel, C ;

Husseini, F ;

Goupil, A ;

Kerbrat, P ;

Misset, JL ;

Bensmaïne, MA ;

Tabah-Fisch, I ;

Pouillart, P .

ANNALS OF ONCOLOGY, 2002, 13 (02) :258-266

[7]

DOROSHOW JH, 2001, P AN M AM SOC CLIN, V20, pA113

[8] Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines [J].

Dunn, TA ;

Schmoll, HJ ;

Grunwald, V ;

Bokemeyer, C ;

Casper, J .

INVESTIGATIONAL NEW DRUGS, 1997, 15 (02) :109-114

[9]

Fink D, 1996, CANCER RES, V56, P4881

[10]

FUKUDA M, 1995, ANTICANCER RES, V15, P393

← 1 2 3 →